Experimentica presents at FELASA 2025
At Experimentica, animal welfare is a core principle of our work. We are dedicated to include refinement studies as part of our internal R&D to improve the well-being of animals involved.
Learn more
ARVO 2025 presentation: Morphological, functional, and behavioral alterations in a microbead-induced mouse glaucoma model
The main aim of the study was to examine the correlation of ocular hypertension with morphological, functional and behavioural parameters in the mouse magnetic microbead glaucoma model.
Learn more
ARVO 2025 presentation: Combined administration of BDNF and CNTF provides superior neuroprotection as compared to BDNF alone in a mouse optic nerve crush model
Glaucoma, a leading cause of blindness and visual impairment worldwide, is characterized by progressive loss of retinal ganglion cells (RGCs) and damage to the optic nerve. Neurotrophic factors, including brain-derived neurotrophic factor (BDNF) and ciliary neurotrophic factor (CNTF), have been extensively studied for their potential to promote RGC survival and axonal regeneration. However, BDNF's efficacy is restricted by receptor desensitization, while CNTF alone often induces inflammation and gliosis, limiting its therapeutic potential. This study was aimed at evaluating if a combination of BDNF and CNTF offers synergistic effects, providing superior neuroprotection as compared to either factor alone.
Learn more
ARVO 2025 presentation: Comparison of blue light-induced damage (BLD) in albino and pigmented mice
This study aimed at comparing blue light-induced retinal injury in albino Balb/cJRj and pigmented C57BL/6JRj mice.
Learn more
ARVO 2025 presentation: Triamcinolone delays retinal atrophy in a mouse laser-induced geographic atrophy model
Limited treatment options for patients with geographic atrophy (GA) pose challenges to find proper positive controls in preclinical models. This study aimed to test the efficacy of subconjunctival administration of triamcinolone in a laser-induced mouse model of GA.
Learn more
ARVO 2025 presentation: Phosphate-buffered saline administered intravitreally at P12 blocks neovascularization in the mouse oxygen-induced retinopathy model
Intravitreally injected phosphate-buffered saline (PBS) is known to decrease neovascularization in the mouse oxygen-induced retinopathy (OIR) model, and it is commonly used as a vehicle control in preclinical studies evaluating therapeutic efficacy. This study aimed at evaluating the impact of intravitreally (IVT) administered PBS on neovascularization and revascularization at various timepoints after OIR induction. Aflibercept (Eylea®) was used as a reference control.
Learn more
ARVO 2025 presentation: Human cornea-on-a-chip – opportunities and challenges
Cornea is a tight barrier restricting topically administered drugs’ penetration into the eye. The aim of the study was to create a tight epithelial barrier both with primary and with transformed human corneal cells on a 96-well microfluidic platform.
Learn more
ARVO 2025 presentation: Thioredoxin system and HIF1a pathway activation by oxidative stress in human iPSC-RPE cells
In vitro: Retinal pigment epithelium (RPE) cells exhibit a high susceptibility to reactive oxygen species (ROS) due to their elevated metabolic activity. The accumulation of ROS is a critical factor contributing to the pathogenesis of both dry and wet forms of age-related macular degeneration (AMD). The thioredoxin (TRX) system represents one of the two primary thiol-dependent antioxidant defense mechanisms in mammalian cells. The objective of this study was to investigate the concentration-dependent activation and response of the TRX system to ROS induced by RPE specific exogenous oxidative agent, sodium iodate (NaIO3).
Learn more
ARVO 2025
The ARVO 2025 Annual Meeting is just around the corner! Our teams from Finland, Lithuania, and France are getting ready for the trip to Salt Lake City.
Learn more
The 8th Gene Therapy Summit in Boston – let’s connect!
Experimentica is attending to the 8th Gene Therapy Summit in Boston on March 25-27, 2025. Reach out to schedule a meeting with us!
Learn more
